1. Home
  2. OPEN vs MESO Comparison

OPEN vs MESO Comparison

Compare OPEN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPEN
  • MESO
  • Stock Information
  • Founded
  • OPEN 2014
  • MESO 2004
  • Country
  • OPEN United States
  • MESO Australia
  • Employees
  • OPEN N/A
  • MESO N/A
  • Industry
  • OPEN Real Estate
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • OPEN Finance
  • MESO Health Care
  • Exchange
  • OPEN Nasdaq
  • MESO Nasdaq
  • Market Cap
  • OPEN 1.4B
  • MESO 1.3B
  • IPO Year
  • OPEN N/A
  • MESO N/A
  • Fundamental
  • Price
  • OPEN $4.02
  • MESO $16.12
  • Analyst Decision
  • OPEN Sell
  • MESO Buy
  • Analyst Count
  • OPEN 4
  • MESO 4
  • Target Price
  • OPEN $1.45
  • MESO $18.00
  • AVG Volume (30 Days)
  • OPEN 292.5M
  • MESO 132.6K
  • Earning Date
  • OPEN 08-05-2025
  • MESO 08-28-2025
  • Dividend Yield
  • OPEN N/A
  • MESO N/A
  • EPS Growth
  • OPEN N/A
  • MESO N/A
  • EPS
  • OPEN N/A
  • MESO N/A
  • Revenue
  • OPEN $5,181,000,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • OPEN N/A
  • MESO $196.73
  • Revenue Next Year
  • OPEN $18.95
  • MESO $286.51
  • P/E Ratio
  • OPEN N/A
  • MESO N/A
  • Revenue Growth
  • OPEN 14.07
  • MESO N/A
  • 52 Week Low
  • OPEN $0.51
  • MESO $6.00
  • 52 Week High
  • OPEN $5.87
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • OPEN 60.75
  • MESO 61.10
  • Support Level
  • OPEN $3.06
  • MESO $14.68
  • Resistance Level
  • OPEN $5.87
  • MESO $16.38
  • Average True Range (ATR)
  • OPEN 0.71
  • MESO 0.41
  • MACD
  • OPEN 0.12
  • MESO -0.07
  • Stochastic Oscillator
  • OPEN 54.88
  • MESO 84.97

About OPEN Opendoor Technologies Inc

Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: